RUA.L

RUA Life Sciences Plc
RUA Life Sciences - Result of GM, Issue of Equity and TVR
18th December 2023, 14:34
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 1886X
RUA Life Sciences PLC
18 December 2023
 

18 December 2023

 

 

 

RUA LIFE SCIENCES PLC

 

("RUA" or the "Company")

 

Result of General Meeting, Issue of Equity and Total Voting Rights

 

Director/PDMR Shareholdings

 

RUA Life Sciences plc (AIM: RUA.L), the holding company of a group of medical device businesses focused on the exploitation of long-term implantable biostable polyurathane (Elast-Eon™), announces that all resolutions put to Shareholders at the General Meeting held earlier today in connection with the placing announced by the Company on 30 November 2023 were duly passed.

 

 

Resolution

For

Against

Withheld

Total votes cast



Number of votes

%

Number of votes

%

Number of votes

 

1

Ordinary resolution to authorise the directors to allot shares 

 

7,161,298

 

99.53%

 

34,079

 

0.47%

 

591

 

7,195,377

2

Special resolution to authorise the directors to disapply pre-emption rights

 

7,161,161

 

99.53%

 

34,119

 

0.47%

 

688

 

7,195,280

(1)     Any proxy appointments, which gave discretion to the Chairman have been included in the 'For' votes total.

(2)     Votes "For" and "Against" any resolution are expressed as a percentage of votes validly cast for that resolution. 

(3)     A vote "Withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against", nor in the aggregate figure of total votes cast.

 

 

Director Participation

 

Further to the publication of the Company's interim results for the period ended 30 September 2023, and consequently the end of the Company's close period under MAR, Bill Brown (2.57% shareholder of the Company), Ian Ardill, John McKenna (0.08%) and Lachlan Smith (0.09%) (together, the "Directors") have all subscribed for Subscription Shares at the Issue Price under the Subscription, as set out below.

 

Shareholder

Number of existing Ordinary Shares

 

% of

existing issued ordinary share capital

Number of Subscription Shares subscribed for at the Issue Price

Number of Ordinary Shares held on Admission

 

 

% of

enlarged issued ordinary share capital on Admission

Bill Brown

569,149

2.57%

272,727

 841,876

1.36%

Ian Ardill

-

0.00%

272,727

 272,727

0.44%

John McKenna

18,785

0.08%

90,909

 109,694

0.18%

Lachlan Smith

19,341

0.09%

90,909

 110,250

0.18%

 

For the reasons set out above, the participation by the Directors referred to above in the Subscription is classified as a 'related party transaction' for the purposes of Rule 13 of the AIM Rules. Dr Caroline Stretton, John Ely and Geoffrey Berg, as the independent Directors of the Fundraise, consider, having consulted with Cavendish (as the Company's Nominated Adviser), that the terms of the related party transaction are fair and reasonable insofar as the Company's shareholders are concerned.

 

 

Issue of Eqity and Total Voting Rights

 

Following shareholder approval at the general meeting and conditional on admission, 36,363,636 new ordinary shares have been allotted pursuant to the Placing, 2,784,566 new ordinary shares pursuant to the Retail Offer and 727,272 pursuant to the Subscription,

 

The Company has therefore allotted a total of 39,875,474 new ordinary shares in connection with the Fundraising.

 

Following Admission, the total number of Ordinary Shares in the capital of the Company in issue will be 62,060,272 with each Ordinary Share carrying the right to one vote. There are no shares held in treasury and therefore, following Admission, the total number of voting rights in the Company will be 62,060,272.

 

The above figure may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure, Guidance and Transparency Rules.

 

Capitalised terms used in this announcement have the meaning given to them in the Placing announcement dated 30 November 2023, unless otherwise defined in this announcement.

 

 

For further information contact:

 

RUA Life Sciences

Bill Brown, Chairman

Caroline Stretton, Group Managing Director

 

Tel: +44 (0)1294 317073  

Tel: +44 (0)1294 317073

 

Cavendish Capital Markets Limited                                

(Nominated Adviser and Broker)

Giles Balleny/Dan Hodkinson (Corporate Finance)

Charlie Combe (ECM)

Michael Johnson (Sales)

Tel: +44 (0)20 7220 0500

 

 

PDMR Notification Form

The notification below is made in accordance with the requirements of MAR.

 

1.

Details of the person discharging managerial responsibilities/person closely associated

 

a)

Name:

Bill Brown

 

 

2.

Reason for the notification

 

a)

Position/status:

Executive Chair

 

b)

Initial notification/Amendment:

Initial notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name:

RUA Life Sciences plc

 

 

b)

LEI:

213800BMVB22PVOJ9Z28

 

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary Shares of 5 pence

GB0033360586

b)

Nature of the transaction:

Purchase of Ordinary Shares

 

c)

Price(s) and volume(s):

Price(s)

Volume(s)

11 pence

272,727

d)

Aggregated information:

·Aggregated volume:

·Price:

 

N/A

e)

Date of the transaction:

18 December 2023

 

f)

Place of the transaction:

Outside of a trading venue

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

 

a)

Name:

Ian Ardill

 

 

2.

Reason for the notification

 

a)

Position/status:

Non-Executive Director

 

b)

Initial notification/Amendment:

Initial notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name:

RUA Life Sciences plc

 

 

b)

LEI:

213800BMVB22PVOJ9Z28

 

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary Shares of 5 pence

GB0033360586

b)

Nature of the transaction:

Purchase of Ordinary Shares

 

c)

Price(s) and volume(s):

Price(s)

Volume(s)

11 pence

272,727

d)

Aggregated information:

·Aggregated volume:

·Price:

 

N/A

e)

Date of the transaction:

18 December 2023

 

f)

Place of the transaction:

Outside of a trading venue

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

 

a)

Name:

Lachlan Smith

 

 

2.

Reason for the notification

 

a)

Position/status:

Chief Financial Officer

 

b)

Initial notification/Amendment:

Initial notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name:

RUA Life Sciences plc

 

 

b)

LEI:

213800BMVB22PVOJ9Z28

 

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary Shares of 5 pence

GB0033360586

b)

Nature of the transaction:

Purchase of Ordinary Shares

 

c)

Price(s) and volume(s):

Price(s)

Volume(s)

11 pence

90,909

d)

Aggregated information:

·Aggregated volume:

·Price:

 

N/A

e)

Date of the transaction:

18 December 2023

 

f)

Place of the transaction:

Outside of a trading venue

 

 

 

1.

Details of the person discharging managerial responsibilities/person closely associated

 

a)

Name:

John McKenna

 

2.

Reason for the notification

 

a)

Position/status:

Non-Executive Director

 

b)

Initial notification/Amendment:

Initial notification

 

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name:

RUA Life Sciences plc

 

 

b)

LEI:

213800BMVB22PVOJ9Z28

 

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary Shares of 5 pence

GB0033360586

b)

Nature of the transaction:

Purchase of Ordinary Shares

 

c)

Price(s) and volume(s):

Price(s)

Volume(s)

11 pence

90,909

d)

Aggregated information:

·Aggregated volume:

·Price:

 

N/A

e)

Date of the transaction:

18 December 2023

 

f)

Place of the transaction:

Outside of a trading venue

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ROMFLFFSFELTLIV]]>
TwitterFacebookLinkedIn